A recent high-throughput screening study performed by Griner M. et al. confirmed these results demonstrating that the combination of NVP-BEZ235 and the BTK inhibitor ibrutinib is highly synergistic in killing ABC-subtype DLBCL cell lines in vitro [233]. Here, BTK is linked to diffuse large B-cell lymphoma.